Korean J Ophthalmol.  2017 Dec;31(6):538-547. 10.3341/kjo.2017.0017.

Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma

Affiliations
  • 1Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. exo70@naver.com
  • 2Center for Creative Biomedical Scientists, Chonnam National University, Gwangju, Korea.

Abstract

PURPOSE
To evaluate the long-term efficacy and safety of intracameral bevacizumab in patients with neovascular glaucoma.
METHODS
This retrospective study included 26 eyes of 26 neovascular glaucoma patients who received intracameral bevacizumab injection between January 2013 and May 2015, and were followed-up for at least 1 year. All patients were treated with topical and/or systemic intraocular pressure (IOP)-lowering medications, intracameral bevacizumab, and panretinal photocoagulation (PRP). The main outcome measures were changes in visual acuity, IOP, and neovascularization of the iris (NVI) and the anterior chamber angle (NVA). To assess the safety of intracameral bevacizumab, corneal endothelial changes were also determined using specular microscopy. Patients whose IOP was uncontrolled received IOP-lowering surgery. Clinical factors associated with IOP-lowering surgery were also investigated.
RESULTS
In all patients, intracameral bevacizumab resulted in a rapid and marked reduction of IOP, NVI, and NVA within 1 week. At 12 months after initial injection, 19 of 26 eyes (73%) underwent IOP-lowering surgery. The average interval between initial injection and surgical treatment was 33.6 ± 26.9 days. Baseline IOP (p = 0.018), NVA grade (p = 0.029), and incomplete PRP (p = 0.005) were identified as predictive factors for IOP-lowering surgery. During the follow-up period, there were no statistically significant corneal endothelial changes after intracameral bevacizumab injection.
CONCLUSIONS
During 1 year of follow-up after intracameral bevacizumab, the procedure was found to be safe for the corneal endothelium. However, the IOP-lowering effect was transient, and 73% of patients eventually required IOP-lowering surgery. Predictive factors for IOP-lowering surgery were high baseline IOP and NVA grade, and incomplete PRP.

Keyword

Bevacizumab; Intracameral injection; Neovascular glaucoma; Vascular endothelial growth factor

MeSH Terms

Anterior Chamber
Bevacizumab*
Endothelium, Corneal
Follow-Up Studies
Glaucoma, Neovascular*
Humans
Intraocular Pressure
Iris
Light Coagulation
Microscopy
Outcome Assessment (Health Care)
Retrospective Studies
Vascular Endothelial Growth Factor A
Visual Acuity
Bevacizumab
Vascular Endothelial Growth Factor A

Figure

  • Fig. 1 The changes in intraocular pressure (IOP) after intracameral bevacizumab injection. Of 26 eyes, IOP in 22 eyes could be controlled with injection, but 4 eyes received anti-glaucoma surgery 1 week after injection. At 1 month, 14 eyes received the surgery, and the number increased to 19 eyes at 12 months after injection. IOP in the eyes of the non-surgical group was maintained <20 mmHg after treatment. The surgical group showed poor response to injection, but, after surgery IOP also stabilized.


Reference

1. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol. 2009; 24:113–121.
2. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001; 108:1767–1776.
3. Doft BH, Blankenship G. Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1984; 91:1453–1457.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480–1487.
5. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998; 105:232–237.
6. Sasamoto Y, Oshima Y, Miki A, et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study. J Ocul Pharmacol Ther. 2012; 28:41–48.
7. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002; 120:1644–1650.
8. Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008; 28:696–702.
9. Wolf A, von Jagow B, Ulbig M, Haritoglou C. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica. 2011; 226:51–56.
10. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008; 146:508–512.
11. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009; 18:632–637.
12. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115:1571–1580.
13. Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol. 1978; 10:488–491.
14. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley and Sons;1981. p. 212–213.
15. Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010; 248:1601–1609.
16. Bhagat PR, Agrawal KU, Tandel D. Study of the effect of injection bevacizumab through various routes in neovascular glaucoma. J Curr Glaucoma Pract. 2016; 10:39–48.
17. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007; 16:437–439.
18. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol. 2011; 129:145–150.
19. Nakano S, Nakamuro T, Yokoyama K, et al. Prognostic factor analysis of intraocular pressure with neovascular glaucoma. J Ophthalmol. 2016; 2016:1205895.
20. Hosny MH, Zayed MA, Shalaby AM, Eissa IM. Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther. 2009; 25:513–517.
21. Park HY, Kim SJ, Lee HB, et al. Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea. 2008; 27:1151–1155.
Full Text Links
  • KJO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr